C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis
Xiyuan Bai,Shaobin Shang,Marcela Henao-Tamayo,Randall J. Basaraba,Alida R. Ovrutsky,Jennifer L. Matsuda,Katsuyuki Takeda,Mallory M. Chan,Azzeddine Dakhama,William H. Kinney,Jessica Trostel,An Bai,Jennifer R. Honda,Rosane Achcar,John M. Hartney,Leo A. B. Joosten,Soohyun Kim,Ian M. Orme,Charles A. Dinarello,Charles A. Dinarello,Diane J. Ordway,Edward D. Chan +21 more
TL;DR: IL-32γ enhances host immunity to MTB, and lungs of patients with tuberculosis showed increased IL-32 expression, particularly in macrophages of granulomas and airway epithelial cells but also B cells and T cells.
Journal ArticleDOI
Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein
TL;DR: The results suggest that the commonality between IL-13 and IL-4 in inducing IL-1Ra synthesis results from the engagement of a subunit common to both receptors.
Journal ArticleDOI
Plasmapheresis for fulminant meningococcemia.
Journal ArticleDOI
In vitro enhanced throboxane B2 release by polymorhonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1
TL;DR: The ability of rat peritoneal macrophages and human PMNs to synthesize thromboxane A2 (detected as TxB2) in response to human recombinant interleukin 1 (hrIL1) was examined.
Journal ArticleDOI
Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.
A. Mario Marcondes,A. Mario Marcondes,David M. Hockenbery,David M. Hockenbery,Marina Lesnikova,Charles A. Dinarello,Charles A. Dinarello,Ann E. Woolfrey,Ann E. Woolfrey,Terry Gernsheimer,Terry Gernsheimer,Mahmoud Loghman-Adham,David Gelmont,Barry E. Storer,Barry E. Storer,John A. Hansen,John A. Hansen,H. Joachim Deeg,H. Joachim Deeg +18 more
TL;DR: Findings show that AAT is well tolerated and has efficacy in the treatment of steroid-refractory severe acute GVHD, and further studies are warranted.